Introduction
Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), are devastating conditions that affect millions of people worldwide. A common pathological hallmark underlying these disorders is the accumulation of misfolded and aggregated proteins — such as hyperphosphorylated tau, α-synuclein, mutant huntingtin, and postsynaptic density protein-95 (PSD-95) — that disrupt neuronal function and ultimately lead to progressive cell death.
Conventional therapeutic approaches, including small-molecule inhibitors and monoclonal antibodies, have achieved limited success against these aggregation-prone proteins, many of which have long been considered “undruggable” targets. In recent years, targeted protein degradation (TPD) has emerged as a transformative strategy that co-opts the cell’s endogenous protein quality control machinery — the ubiquitin-proteasome system and the autophagy-lysosome pathway — to eliminate disease-driving proteins at the post-translational level.
As a pioneer in preclinical drug discovery, Creative Biolabs offers comprehensive ligand design services for heterobifunctional degraders targeting neurodegenerative disease-related proteins. With deep expertise spanning computational chemistry, ligand discovery, and degrader optimization, Creative Biolabs is uniquely positioned to help researchers overcome the challenges of designing brain-penetrant degraders for these notoriously difficult targets.
Huntingtin-Targeting Degrader Ligand Design
Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, which encodes an abnormally expanded polyglutamine (polyQ) tract near the N-terminus of the huntingtin protein. Mutant huntingtin (mHTT) adopts a β-sheet-rich conformation that drives the formation of toxic fibrillar and non-fibrillar aggregates, particularly in striatal neurons, leading to progressive motor dysfunction, cognitive decline, and psychiatric symptoms.
HTT is a large 348 kDa scaffolding protein composed primarily of HEAT (HTT, elongation factor 3, protein phosphatase 2A, TOR1) repeats that mediate conformational changes and protein-protein interactions. The N-terminal region harbors ubiquitination, sumoylation, and nuclear export signals, followed by the polyQ and polyproline tracts that are central to disease pathogenesis. Current therapeutic strategies — antisense oligonucleotides, RNA interference — face significant hurdles in achieving effective blood-brain barrier (BBB) penetration following systemic delivery.
Heterobifunctional degraders offer an alternative modality for HTT lowering. The polyglutamine binding peptide 1 (QBP1) has attracted particular attention as a ligand warhead because it selectively recognizes the expanded polyQ tract in mHTT while sparing the normal polyQ motif in wild-type HTT. By conjugating QBP1 or structurally optimized derivatives with ligands for E3 ubiquitin ligases such as cereblon (CRBN) or von Hippel-Lindau (VHL), degrader molecules can recruit mHTT to the ubiquitin-proteasome system for selective proteasomal degradation. Creative Biolabs provides structure-based ligand design for HTT-targeting degraders, leveraging computational platforms and display-based screening systems to generate high-affinity peptide ligands, engineered antibodies, and small-molecule binders specific for mHTT.
Tau-Targeting Degrader Ligand Design
Tau is a microtubule-associated protein predominantly expressed in neurons, where it stabilizes microtubules and supports axonal transport. Encoded by the MAPT gene on chromosome 17q21, alternative splicing of exons 2, 3, and 10 generates six major isoforms in the adult human brain. Under pathological conditions, tau becomes hyperphosphorylated and dissociates from microtubules, forming intracellular paired helical filaments and neurofibrillary tangles — the hallmark lesions of Alzheimer’s disease and related tauopathies, including frontotemporal dementia (FTD).
Heterobifunctional degraders targeting tau represent one of the most advanced applications of TPD in neurodegenerative disease. In a seminal proof-of-concept study, a KEAP1-recruiting degrader incorporating a tau-binding peptide and a poly-D-Arg cell-penetrating sequence demonstrated strong in vitro binding to both KEAP1 (Kd = 22.8 nM) and tau (Kd = 763 nM), leading to time- and concentration-dependent tau degradation confirmed by western blotting and flow cytometry. More recently, reported that selective degradation of hyperphosphorylated tau via heterobifunctional degraders ameliorated cognitive deficits in AD mouse models, providing compelling in vivo validation for this therapeutic strategy.
Creative Biolabs’ tau ligand design services encompass multiple modalities, including small molecules, peptides, and recombinant antibodies. Based on a rational design platform, ligands can be paired with different E3 ligase-binding moieties — such as VHL or KEAP1 — to optimize degradation efficiency and selectivity. The resulting degrader molecules exhibit strong in vitro tau binding, improved cell permeability, and concentration-dependent downregulation of intracellular tau levels.
α-Synuclein-Targeting Degrader Ligand Design
α-Synuclein is a 140-amino acid presynaptic protein of 18–20 kDa that has emerged as a central pathogenic factor in both familial and sporadic forms of Parkinson’s disease. The protein comprises an amphipathic lysine-rich N-terminus, a central hydrophobic non-amyloid-β component (NAC) domain spanning residues 65–90, and a disordered acidic C-terminal tail. The NAC domain is indispensable for α-synuclein aggregation — deletion of segments within this region drastically reduces oligomerization and fibrillogenesis — and the aggregated protein constitutes the major component of Lewy bodies, the pathological hallmark of PD.
Unlike traditional approaches that interfere with α-synuclein propagation, reduce its production, or inhibit aggregation, heterobifunctional degraders act by recruiting α-synuclein to an E3 ubiquitin ligase for ubiquitination and subsequent proteasomal degradation. Several tricyclic phenothiazine analogs, including SIL23, SIL5, and SIL26, have exhibited reasonable in vitro selectivity for α-synuclein oligomerization and fibrillogenesis; however, their limited metabolic stability and moderate affinity for α-synuclein aggregates restrict their utility as degrader ligands.
Creative Biolabs addresses these challenges through comprehensive α-synuclein ligand design services that combine structure-based computational methods for in silico screening, phage display for peptide and antibody identification, and rational engineering of existing ligands to improve selectivity and binding affinity. By leveraging the structural characteristics of α-synuclein — particularly the aggregation-prone NAC domain — high-throughput techniques facilitate the discovery of optimal ligands that enable the design of potent and specific degraders for this historically challenging target.
PSD-95-Targeting Degrader Ligand Design
PSD-95 is a prominent member of the membrane-associated guanylate kinase (MAGUK) family and serves as a master scaffolding protein at excitatory synapses. It contains three PDZ (PSD-95/Discs large/ZO-1) domains, an SH3 domain, and a non-catalytic guanylate kinase domain. Through its PDZ domains, PSD-95 simultaneously binds the C-terminal tails of N-methyl-D-aspartate (NMDA) receptor GluN2 subunits and neuronal nitric oxide synthase (nNOS), thereby assembling a ternary NMDAR/PSD-95/nNOS signaling complex that couples calcium influx to neurotoxic nitric oxide production.
This signaling hub has been validated as a therapeutic target across multiple neurological indications. The dimeric peptide inhibitor Tat-NPEG4(IETDV)2 binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented affinity of 4.6 nM and displays extensive protease resistance in human plasma. In mouse models of focal cerebral ischemia, a single intravenous injection reduced infarct volume by 40% and restored motor function. The clinical-stage inhibitor nerinetide (Tat-NR2B9c) has advanced to phase III trials for acute ischemic stroke, further validating the PSD-95/nNOS interaction as a clinically relevant target.
Creative Biolabs’ PSD-95 ligand design services build on extensive knowledge of PSD-95 protein-protein interactions to develop peptide-based ligands targeting individual PDZ domains with nanomolar affinity. Dimeric ligands engineered with short polyethylene glycol (PEG) linkers achieve markedly enhanced binding compared to monomeric counterparts. Ligands derived from the NR2B C-terminal sequence (Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val), as well as those targeting the interaction interfaces of nNOS and cysteine-rich protein (CRIPT), provide versatile starting points for degrader development. Creative Biolabs further offers inhibitor modification and optimization services to generate functional degraders that disrupt PSD-95-mediated pathological signaling with high specificity.
Overcoming the Blood-Brain Barrier Challenge
A central challenge in developing heterobifunctional degraders for neurodegenerative indications is achieving sufficient brain exposure. The BBB restricts the passage of most large and hydrophilic molecules, and many degrader candidates — with molecular weights often exceeding 800 Da — fall outside the physicochemical space associated with favorable CNS penetration. Furthermore, achieving pathological specificity — selectively degrading disease-associated protein species while sparing their physiologically essential counterparts — remains a critical consideration. For example, wholesale depletion of tau or α-synuclein could compromise microtubule stability or synaptic vesicle trafficking, respectively.
Creative Biolabs addresses these challenges through multiple complementary strategies. Linker composition and length are systematically optimized to balance potency with drug-like properties that favor BBB penetration. Ligand warheads are designed or engineered to discriminate between pathological conformers — such as hyperphosphorylated tau or expanded polyQ-containing mHTT — and their wild-type counterparts. The comprehensive service platform integrates structural biology, computational chemistry, medicinal chemistry, and biological validation to deliver degrader candidates with favorable brain penetration, target selectivity, and therapeutic potential.
Conclusion
The application of targeted protein degradation to neurodegenerative disease represents one of the most promising frontiers in modern drug discovery. By harnessing the cell’s intrinsic degradation machinery, heterobifunctional degraders offer a fundamentally new way to eliminate the misfolded and aggregated proteins that drive diseases like Alzheimer’s, Parkinson’s, Huntington’s, and stroke-related brain injury — targets that have largely resisted conventional small-molecule and biologic approaches.
Creative Biolabs stands at the forefront of this emerging field, offering end-to-end ligand design services for degraders targeting huntingtin, tau, α-synuclein, and PSD-95. From in silico screening and structure-based design to phage display, peptide engineering, and linker optimization, our multidisciplinary team provides the expertise and technological platforms needed to advance degrader programs from concept to lead candidate. For researchers seeking to explore the therapeutic potential of targeted protein degradation in neurodegenerative disease, Creative Biolabs is the partner of choice.
Frequently Asked Questions
Q1: What makes heterobifunctional degraders suitable for neurodegenerative disease targets?
Unlike conventional inhibitors that merely block protein activity, heterobifunctional degraders eliminate target proteins entirely through the ubiquitin-proteasome system. This catalytic mechanism is particularly advantageous for aggregation-prone proteins such as mutant huntingtin, tau, and α-synuclein, where simple functional blockade is insufficient to reverse pathology. Additionally, degraders can target proteins previously considered “undruggable” because they do not require a well-defined active site — a surface-binding ligand is sufficient to recruit the target to an E3 ligase for ubiquitination and degradation.
Q2: How does Creative Biolabs address the blood-brain barrier challenge?
Creative Biolabs employs multiple strategies to optimize brain penetration of degrader candidates. These include systematic linker optimization to reduce molecular weight and polar surface area, the use of computational models to predict CNS penetration, and the selection of ligand warheads with favorable physicochemical properties. In addition, peptide-based ligands can be conjugated with cell-penetrating sequences (e.g., poly-D-Arg, Tat) to enhance cellular and brain uptake.
Q3: Can heterobifunctional degraders distinguish between pathological and wild-type proteins?
Yes, and this selectivity is a key design consideration. For huntingtin, QBP1-based ligands preferentially recognize the expanded polyQ tract in mHTT while sparing the shorter polyQ stretch in wild-type HTT. For tau, ligands can be designed to target hyperphosphorylated or conformationally altered species associated with neurofibrillary tangles. Creative Biolabs’ structure-based design approach leverages these disease-specific conformational differences to engineer ligands with the required degree of pathological selectivity.
Q4: What ligand modalities does Creative Biolabs offer for protein degrader development?
Creative Biolabs provides ligands in multiple formats: small molecules identified through in silico screening and structure-based computational methods, peptides generated via phage display and rational design, and recombinant antibodies developed through established antibody engineering platforms. Peptide-based dimeric ligands, in particular, have shown remarkable success — such as the PSD-95 PDZ1-2 binder with 4.6 nM affinity — demonstrating the power of multivalent interactions for achieving high-affinity target engagement.
References
Hyun, Soonsil, and Dongyun Shin. “Chemical-mediated targeted protein degradation in neurodegenerative diseases.” Life 11.7 (2021): 607. CC BY 4.0. https://doi.org/10.3390/life11070607